Annual FCF
-$60.33 M
+$88.40 M+59.44%
31 December 2023
Summary:
Heron Therapeutics annual free cash flow is currently -$60.33 million, with the most recent change of +$88.40 million (+59.44%) on 31 December 2023. During the last 3 years, it has risen by +$131.30 million (+68.52%). HRTX annual FCF is now -770.82% below its all-time high of $8.99 million, reached on 31 December 2006.HRTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$2.94 M
+$8.18 M+156.10%
30 September 2024
Summary:
Heron Therapeutics quarterly free cash flow is currently $2.94 million, with the most recent change of +$8.18 million (+156.10%) on 30 September 2024. Over the past year, it has increased by +$12.91 million (+129.48%). HRTX quarterly FCF is now -85.58% below its all-time high of $20.39 million, reached on 31 March 2006.HRTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$9.61 M
+$12.91 M+57.33%
30 September 2024
Summary:
Heron Therapeutics TTM free cash flow is currently -$9.61 million, with the most recent change of +$12.91 million (+57.33%) on 30 September 2024. Over the past year, it has increased by +$90.88 million (+90.43%). HRTX TTM FCF is now -166.98% below its all-time high of $14.35 million, reached on 31 March 2006.HRTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +59.4% | +129.5% | +90.4% |
| 3 y3 years | +68.5% | +105.4% | +95.5% |
| 5 y5 years | +70.0% | +112.0% | +93.0% |
HRTX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.8% | at high | +105.4% | at high | +95.5% |
| 5 y | 5 years | at high | +70.8% | at high | +104.6% | at high | +95.5% |
| alltime | all time | -770.8% | +70.8% | -85.6% | +104.6% | -167.0% | +95.5% |
Heron Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.94 M(-156.1%) | -$9.61 M(-57.3%) |
| June 2024 | - | -$5.24 M(-44.9%) | -$22.52 M(-49.6%) |
| Mar 2024 | - | -$9.52 M(-531.6%) | -$44.73 M(-25.9%) |
| Dec 2023 | -$60.33 M(-59.4%) | $2.21 M(-122.1%) | -$60.33 M(-40.0%) |
| Sept 2023 | - | -$9.97 M(-63.7%) | -$100.49 M(-21.3%) |
| June 2023 | - | -$27.44 M(+9.2%) | -$127.63 M(-1.0%) |
| Mar 2023 | - | -$25.12 M(-33.8%) | -$128.88 M(-13.4%) |
| Dec 2022 | -$148.74 M(-27.9%) | -$37.95 M(+2.3%) | -$148.74 M(-4.9%) |
| Sept 2022 | - | -$37.11 M(+29.3%) | -$156.44 M(-10.1%) |
| June 2022 | - | -$28.70 M(-36.2%) | -$174.02 M(-16.6%) |
| Mar 2022 | - | -$44.98 M(-1.5%) | -$208.63 M(+1.1%) |
| Dec 2021 | -$206.38 M(+7.7%) | -$45.65 M(-16.5%) | -$206.38 M(-4.4%) |
| Sept 2021 | - | -$54.70 M(-13.6%) | -$215.78 M(+5.9%) |
| June 2021 | - | -$63.31 M(+48.2%) | -$203.76 M(+2.7%) |
| Mar 2021 | - | -$42.72 M(-22.4%) | -$198.48 M(+3.6%) |
| Dec 2020 | -$191.63 M(+45.5%) | -$55.05 M(+29.0%) | -$191.63 M(+14.4%) |
| Sept 2020 | - | -$42.69 M(-26.4%) | -$167.47 M(+12.2%) |
| June 2020 | - | -$58.03 M(+61.8%) | -$149.20 M(+28.1%) |
| Mar 2020 | - | -$35.87 M(+16.2%) | -$116.45 M(-11.6%) |
| Dec 2019 | -$131.73 M(-34.5%) | -$30.88 M(+26.4%) | -$131.73 M(-4.4%) |
| Sept 2019 | - | -$24.42 M(-3.4%) | -$137.82 M(-9.8%) |
| June 2019 | - | -$25.27 M(-50.6%) | -$152.73 M(-19.4%) |
| Mar 2019 | - | -$51.16 M(+38.4%) | -$189.52 M(-5.7%) |
| Dec 2018 | -$200.98 M(+16.3%) | -$36.96 M(-6.0%) | -$200.98 M(-5.3%) |
| Sept 2018 | - | -$39.33 M(-36.6%) | -$212.30 M(-0.6%) |
| June 2018 | - | -$62.06 M(-0.9%) | -$213.50 M(+16.1%) |
| Mar 2018 | - | -$62.62 M(+29.7%) | -$183.95 M(+6.4%) |
| Dec 2017 | -$172.85 M(+26.0%) | -$48.28 M(+19.1%) | -$172.85 M(+5.5%) |
| Sept 2017 | - | -$40.53 M(+24.7%) | -$163.78 M(+2.4%) |
| June 2017 | - | -$32.52 M(-36.9%) | -$159.90 M(+2.8%) |
| Mar 2017 | - | -$51.52 M(+31.4%) | -$155.57 M(+13.4%) |
| Dec 2016 | -$137.23 M(+72.4%) | -$39.21 M(+7.0%) | -$137.23 M(+13.0%) |
| Sept 2016 | - | -$36.65 M(+30.0%) | -$121.47 M(+15.7%) |
| June 2016 | - | -$28.19 M(-15.1%) | -$104.97 M(+13.1%) |
| Mar 2016 | - | -$33.19 M(+41.5%) | -$92.80 M(+16.6%) |
| Dec 2015 | -$79.61 M(+29.0%) | -$23.45 M(+16.4%) | -$79.61 M(+13.7%) |
| Sept 2015 | - | -$20.14 M(+25.7%) | -$70.04 M(+1.2%) |
| June 2015 | - | -$16.02 M(-19.9%) | -$69.22 M(+5.0%) |
| Mar 2015 | - | -$20.00 M(+44.1%) | -$65.95 M(+6.8%) |
| Dec 2014 | -$61.72 M(+45.4%) | -$13.88 M(-28.2%) | -$61.72 M(+7.1%) |
| Sept 2014 | - | -$19.32 M(+51.5%) | -$57.64 M(+11.6%) |
| June 2014 | - | -$12.75 M(-19.1%) | -$51.65 M(+3.7%) |
| Mar 2014 | - | -$15.77 M(+61.0%) | -$49.82 M(+17.4%) |
| Dec 2013 | -$42.45 M(+136.1%) | -$9.79 M(-26.5%) | -$42.45 M(+8.3%) |
| Sept 2013 | - | -$13.33 M(+22.0%) | -$39.20 M(+36.3%) |
| June 2013 | - | -$10.93 M(+30.1%) | -$28.76 M(+31.6%) |
| Mar 2013 | - | -$8.40 M(+28.2%) | -$21.85 M(+21.5%) |
| Dec 2012 | -$17.98 M(+118.4%) | -$6.55 M(+127.1%) | -$17.98 M(+25.8%) |
| Sept 2012 | - | -$2.88 M(-28.1%) | -$14.29 M(+0.7%) |
| June 2012 | - | -$4.01 M(-11.4%) | -$14.19 M(+20.9%) |
| Mar 2012 | - | -$4.53 M(+58.3%) | -$11.74 M(+42.6%) |
| Dec 2011 | -$8.23 M(+48.1%) | -$2.86 M(+2.8%) | -$8.23 M(+30.8%) |
| Sept 2011 | - | -$2.78 M(+78.0%) | -$6.29 M(+1.0%) |
| June 2011 | - | -$1.56 M(+52.7%) | -$6.23 M(-4.3%) |
| Mar 2011 | - | -$1.02 M(+10.9%) | -$6.51 M(+17.1%) |
| Dec 2010 | -$5.56 M(-49.5%) | -$923.00 K(-66.1%) | -$5.56 M(-16.2%) |
| Sept 2010 | - | -$2.72 M(+47.6%) | -$6.64 M(+8.4%) |
| June 2010 | - | -$1.84 M(+2426.0%) | -$6.12 M(-23.5%) |
| Mar 2010 | - | -$73.00 K(-96.4%) | -$8.00 M(-27.3%) |
| Dec 2009 | -$11.00 M(-55.2%) | -$2.00 M(-9.3%) | -$11.00 M(-26.9%) |
| Sept 2009 | - | -$2.21 M(-40.7%) | -$15.05 M(-15.5%) |
| June 2009 | - | -$3.72 M(+21.1%) | -$17.81 M(-12.8%) |
| Mar 2009 | - | -$3.07 M(-49.2%) | -$20.43 M(-16.9%) |
| Dec 2008 | -$24.57 M(+38.3%) | -$6.05 M(+21.6%) | -$24.57 M(+5.7%) |
| Sept 2008 | - | -$4.97 M(-21.6%) | -$23.26 M(-1.5%) |
| June 2008 | - | -$6.34 M(-12.2%) | -$23.60 M(+25.6%) |
| Mar 2008 | - | -$7.22 M(+52.5%) | -$18.79 M(+5.8%) |
| Dec 2007 | -$17.76 M | -$4.73 M(-11.0%) | -$17.76 M(+9.3%) |
| Sept 2007 | - | -$5.32 M(+249.1%) | -$16.24 M(+11.4%) |
| June 2007 | - | -$1.52 M(-75.4%) | -$14.58 M(-17.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$6.19 M(+92.7%) | -$17.59 M(-295.5%) |
| Dec 2006 | $8.99 M(-214.7%) | -$3.21 M(-12.0%) | $8.99 M(-9.1%) |
| Sept 2006 | - | -$3.65 M(-19.4%) | $9.89 M(-16.9%) |
| June 2006 | - | -$4.53 M(-122.2%) | $11.90 M(-17.1%) |
| Mar 2006 | - | $20.39 M(-981.9%) | $14.35 M(-283.0%) |
| Dec 2005 | -$7.84 M(+2.9%) | -$2.31 M(+40.6%) | -$7.84 M(+13.4%) |
| Sept 2005 | - | -$1.64 M(-21.1%) | -$6.92 M(+3.2%) |
| June 2005 | - | -$2.08 M(+15.5%) | -$6.70 M(-11.1%) |
| Mar 2005 | - | -$1.80 M(+30.2%) | -$7.54 M(-1.0%) |
| Dec 2004 | -$7.62 M(+15.8%) | -$1.39 M(-3.1%) | -$7.62 M(-1.2%) |
| Sept 2004 | - | -$1.43 M(-51.0%) | -$7.71 M(+7.1%) |
| June 2004 | - | -$2.92 M(+55.1%) | -$7.20 M(+8.3%) |
| Mar 2004 | - | -$1.88 M(+27.7%) | -$6.65 M(+1.0%) |
| Dec 2003 | -$6.58 M(+18.4%) | -$1.48 M(+60.5%) | -$6.58 M(+4.0%) |
| Sept 2003 | - | -$919.00 K(-61.3%) | -$6.33 M(-5.4%) |
| June 2003 | - | -$2.37 M(+30.5%) | -$6.69 M(+10.6%) |
| Mar 2003 | - | -$1.82 M(+48.9%) | -$6.05 M(+8.7%) |
| Dec 2002 | -$5.56 M(-17.8%) | -$1.22 M(-4.8%) | -$5.56 M(-16.2%) |
| Sept 2002 | - | -$1.28 M(-25.9%) | -$6.64 M(-9.0%) |
| June 2002 | - | -$1.73 M(+29.9%) | -$7.29 M(+10.4%) |
| Mar 2002 | - | -$1.33 M(-42.0%) | -$6.60 M(-2.4%) |
| Dec 2001 | -$6.77 M(+105.4%) | -$2.29 M(+18.4%) | -$6.77 M(+12.1%) |
| Sept 2001 | - | -$1.94 M(+86.3%) | -$6.04 M(+17.7%) |
| June 2001 | - | -$1.04 M(-30.5%) | -$5.13 M(+8.8%) |
| Mar 2001 | - | -$1.50 M(-4.4%) | -$4.72 M(+43.1%) |
| Dec 2000 | -$3.29 M(+229.5%) | -$1.56 M(+51.8%) | -$3.29 M(+222.9%) |
| Sept 2000 | - | -$1.03 M(+64.9%) | -$1.02 M(<-9900.0%) |
| June 2000 | - | -$624.90 K(+735.4%) | $300.00(-100.0%) |
| Mar 2000 | - | -$74.80 K(-110.5%) | -$874.80 K(-12.5%) |
| Dec 1999 | -$1.00 M(-76.7%) | $709.70 K(-7416.5%) | -$1.00 M(-37.9%) |
| Sept 1999 | - | -$9700.00(-99.4%) | -$1.61 M(+0.6%) |
| June 1999 | - | -$1.50 M(+650.0%) | -$1.60 M(+45.5%) |
| Mar 1999 | - | -$200.00 K(-300.0%) | -$1.10 M(-74.4%) |
| Dec 1998 | -$4.30 M(+53.6%) | $100.00 K(>+9900.0%) | -$4.30 M(-14.0%) |
| Sept 1998 | - | $0.00(-100.0%) | -$5.00 M(-10.7%) |
| June 1998 | - | -$1.00 M(-70.6%) | -$5.60 M(-12.5%) |
| Mar 1998 | - | -$3.40 M(+466.7%) | -$6.40 M(+128.6%) |
| Dec 1997 | -$2.80 M(-58.8%) | -$600.00 K(0.0%) | -$2.80 M(+3.7%) |
| Sept 1997 | - | -$600.00 K(-66.7%) | -$2.70 M(-18.2%) |
| June 1997 | - | -$1.80 M(-1000.0%) | -$3.30 M(+17.9%) |
| Mar 1997 | - | $200.00 K(-140.0%) | -$2.80 M(-58.8%) |
| Dec 1996 | -$6.80 M(-27.7%) | -$500.00 K(-58.3%) | -$6.80 M(-28.4%) |
| Sept 1996 | - | -$1.20 M(-7.7%) | -$9.50 M(-13.6%) |
| June 1996 | - | -$1.30 M(-65.8%) | -$11.00 M(-12.7%) |
| Mar 1996 | - | -$3.80 M(+18.8%) | -$12.60 M(+34.0%) |
| Dec 1995 | -$9.40 M(+2.2%) | -$3.20 M(+18.5%) | -$9.40 M(+1.1%) |
| Sept 1995 | - | -$2.70 M(-6.9%) | -$9.30 M(0.0%) |
| June 1995 | - | -$2.90 M(+383.3%) | -$9.30 M(+2.2%) |
| Mar 1995 | - | -$600.00 K(-80.6%) | -$9.10 M(-1.1%) |
| Dec 1994 | -$9.20 M(-28.7%) | -$3.10 M(+14.8%) | -$9.20 M(+3.4%) |
| Sept 1994 | - | -$2.70 M(0.0%) | -$8.90 M(-2.2%) |
| June 1994 | - | -$2.70 M(+285.7%) | -$9.10 M(-17.3%) |
| Mar 1994 | - | -$700.00 K(-75.0%) | -$11.00 M(-14.7%) |
| Dec 1993 | -$12.90 M(+104.8%) | -$2.80 M(-3.4%) | -$12.90 M(-3.7%) |
| Sept 1993 | - | -$2.90 M(-37.0%) | -$13.40 M(+32.7%) |
| June 1993 | - | -$4.60 M(+76.9%) | -$10.10 M(+53.0%) |
| Mar 1993 | - | -$2.60 M(-21.2%) | -$6.60 M(+4.8%) |
| Dec 1992 | -$6.30 M(+61.5%) | -$3.30 M(-925.0%) | -$6.30 M(+40.0%) |
| Sept 1992 | - | $400.00 K(-136.4%) | -$4.50 M(-27.4%) |
| June 1992 | - | -$1.10 M(-52.2%) | -$6.20 M(+17.0%) |
| Mar 1992 | - | -$2.30 M(+53.3%) | -$5.30 M(+39.5%) |
| Dec 1991 | -$3.90 M(+8.3%) | -$1.50 M(+15.4%) | -$3.80 M(+31.0%) |
| Sept 1991 | - | -$1.30 M(+550.0%) | -$2.90 M(+7.4%) |
| June 1991 | - | -$200.00 K(-75.0%) | -$2.70 M(-30.8%) |
| Mar 1991 | - | -$800.00 K(+33.3%) | -$3.90 M(+8.3%) |
| Dec 1990 | -$3.60 M(-20.0%) | -$600.00 K(-45.5%) | -$3.60 M(+20.0%) |
| Sept 1990 | - | -$1.10 M(-21.4%) | -$3.00 M(+57.9%) |
| June 1990 | - | -$1.40 M(+180.0%) | -$1.90 M(+280.0%) |
| Mar 1990 | - | -$500.00 K | -$500.00 K |
| Dec 1989 | -$4.50 M | - | - |
FAQ
- What is Heron Therapeutics annual free cash flow?
- What is the all time high annual FCF for Heron Therapeutics?
- What is Heron Therapeutics annual FCF year-on-year change?
- What is Heron Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Heron Therapeutics?
- What is Heron Therapeutics quarterly FCF year-on-year change?
- What is Heron Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Heron Therapeutics?
- What is Heron Therapeutics TTM FCF year-on-year change?
What is Heron Therapeutics annual free cash flow?
The current annual FCF of HRTX is -$60.33 M
What is the all time high annual FCF for Heron Therapeutics?
Heron Therapeutics all-time high annual free cash flow is $8.99 M
What is Heron Therapeutics annual FCF year-on-year change?
Over the past year, HRTX annual free cash flow has changed by +$88.40 M (+59.44%)
What is Heron Therapeutics quarterly free cash flow?
The current quarterly FCF of HRTX is $2.94 M
What is the all time high quarterly FCF for Heron Therapeutics?
Heron Therapeutics all-time high quarterly free cash flow is $20.39 M
What is Heron Therapeutics quarterly FCF year-on-year change?
Over the past year, HRTX quarterly free cash flow has changed by +$12.91 M (+129.48%)
What is Heron Therapeutics TTM free cash flow?
The current TTM FCF of HRTX is -$9.61 M
What is the all time high TTM FCF for Heron Therapeutics?
Heron Therapeutics all-time high TTM free cash flow is $14.35 M
What is Heron Therapeutics TTM FCF year-on-year change?
Over the past year, HRTX TTM free cash flow has changed by +$90.88 M (+90.43%)